On a daily basis I will be posting a Descriptive Question on the facebook page (Link is https://www.facebook.com/studyniti) and a Model answer to the question by the same night in this channel
Do Like the facebook page to get the question
Question of the Today is already posted on facebook page.
Do Like the facebook page to get the question
Question of the Today is already posted on facebook page.
Facebook
Studyniti - Study with Smriti
Studyniti - Study with Smriti. 1,844 likes · 27 talking about this. This is the official Facebook page of Studyniti and will be helpful for all the Banking Exams aspirants
Hydroxychloroquine (HCQ) is a medication used for the prevention and treatment of certain types of malaria, specifically for chloroquine-sensitive malaria. It is also used in treatment of rheumatoid arthritis, lupus, and porphyria cuanea tarda. The government of India banned export of hydroxycloroquine, with immediate effect to ensure sufficient availability of the medicine in the domestic market on April 4. The US President warned about “retaliation” if India did not heed his request for the drug. Following this India partially lifted a ban on the export.
Reasons for HCQ in demand:
The International Journal of Antimicrobial Agents (IJAA), reported that Azithromycin (antibiotic) added to hydroxychloroquine was significantly more efficient for COVID-19 elimination. However, the study was flagged as being too small to draw a definitive conclusion.
By late March, Trump had begun to call the drug a “game changer”, and has since been pushing it. At the end of last month, the Indian Council of Medical Research (ICMR) issued an advisory recommending the use of hydroxychloroquine in asymptomatic healthcare workers treating COVID-19 patients. ICMR also allowed doctors to prescribe it for household contacts of confirmed COVID-19 patients.However, the government has stressed that the drug can only be used in COVID-19 treatment on prescription, and that it should not instill a sense of “false security”. In March, Following the ICMR’s advisory on the drug, various patients and healthcare professionals are learnt to have stocked up on hydroxychloroquine.The drug was then moved to a Schedule H1 status, which means patients who need the drug would have to get a fresh prescription every time they needed to purchase it.
The drug shows antiviral activity in vitro against coronaviruses, and specifically, SARS-CoV-2. Further, the study suggests that prophylaxis (treatment given to prevent disease) with hydroxy-chloroquine at approved doses could prevent SARS-CoV-2 infection and may help to improve viral shedding. Clinical trials are under way in China to know whether the drug can be used for treatment. At the same time, research in other parts of the world has sparked interest in a more expansive use of the anti-malarial medicine. A study by Chinese researchers, for instance, showed that the drug speeded up the recovery of COVID-19 patients who had suffered pneumonia.
Experiments on the drug have also yielded promising results in France. Some experts have called for more tests before hydroxychloroquine is held up as a cure for COVID-19.
But some of the early naysayers of the drug, including the US Food and Drug Administration, have now come around to recommending its use in emergency situations.
Hydroxychloroquine as a COVID-19 palliative, by all accounts, seems to be a work in progress.However, in a world embroiled in a grim struggle against COVID-19, reports of the early success of the drug have generated hope especially in the US, the country hit hardest by the pandemic.
India has one of the lowest manufacturing costs in the world – lower than that of the U.S. and almost half of the cost in Europe. As the country plans to intensify the battle against the novel coronavirus in hotspots, the GoM’s decision must be based on consultations with a wide range of experts — scientists, public health and foreign policy experts and representatives of the pharma industry. India should look up to and invest in biotechnology. India’s biotechnology industry, comprising biopharmaceuticals, bio-services, bio agriculture, bio-industry and bioinformatics is expected to grow at an average rate of around 30% a year and reach $100 billion by 2025. To ensure health security of Indian people, revival of R&D and public sector API manufacturers through bodies like CSIR is necessary.
Reasons for HCQ in demand:
The International Journal of Antimicrobial Agents (IJAA), reported that Azithromycin (antibiotic) added to hydroxychloroquine was significantly more efficient for COVID-19 elimination. However, the study was flagged as being too small to draw a definitive conclusion.
By late March, Trump had begun to call the drug a “game changer”, and has since been pushing it. At the end of last month, the Indian Council of Medical Research (ICMR) issued an advisory recommending the use of hydroxychloroquine in asymptomatic healthcare workers treating COVID-19 patients. ICMR also allowed doctors to prescribe it for household contacts of confirmed COVID-19 patients.However, the government has stressed that the drug can only be used in COVID-19 treatment on prescription, and that it should not instill a sense of “false security”. In March, Following the ICMR’s advisory on the drug, various patients and healthcare professionals are learnt to have stocked up on hydroxychloroquine.The drug was then moved to a Schedule H1 status, which means patients who need the drug would have to get a fresh prescription every time they needed to purchase it.
The drug shows antiviral activity in vitro against coronaviruses, and specifically, SARS-CoV-2. Further, the study suggests that prophylaxis (treatment given to prevent disease) with hydroxy-chloroquine at approved doses could prevent SARS-CoV-2 infection and may help to improve viral shedding. Clinical trials are under way in China to know whether the drug can be used for treatment. At the same time, research in other parts of the world has sparked interest in a more expansive use of the anti-malarial medicine. A study by Chinese researchers, for instance, showed that the drug speeded up the recovery of COVID-19 patients who had suffered pneumonia.
Experiments on the drug have also yielded promising results in France. Some experts have called for more tests before hydroxychloroquine is held up as a cure for COVID-19.
But some of the early naysayers of the drug, including the US Food and Drug Administration, have now come around to recommending its use in emergency situations.
Hydroxychloroquine as a COVID-19 palliative, by all accounts, seems to be a work in progress.However, in a world embroiled in a grim struggle against COVID-19, reports of the early success of the drug have generated hope especially in the US, the country hit hardest by the pandemic.
India has one of the lowest manufacturing costs in the world – lower than that of the U.S. and almost half of the cost in Europe. As the country plans to intensify the battle against the novel coronavirus in hotspots, the GoM’s decision must be based on consultations with a wide range of experts — scientists, public health and foreign policy experts and representatives of the pharma industry. India should look up to and invest in biotechnology. India’s biotechnology industry, comprising biopharmaceuticals, bio-services, bio agriculture, bio-industry and bioinformatics is expected to grow at an average rate of around 30% a year and reach $100 billion by 2025. To ensure health security of Indian people, revival of R&D and public sector API manufacturers through bodies like CSIR is necessary.
This is the detailed answer to the question asked in the facebook page...
Though it is having more words than asked in the exam..its just giving you complete details about the topic..you can take a reference to this answer & write accordingly..
Though it is having more words than asked in the exam..its just giving you complete details about the topic..you can take a reference to this answer & write accordingly..